

Jan 21 1998  
Please do this  
search. FH

Access DB# 35952

## SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: F. Hozier Examiner #: \_\_\_\_\_ Date: 2/21/01  
Art Unit: 1653 Phone Number 305-4508 Serial Number: 091314, 888  
Mail Box and Bldg/Room Location: Box 10601 Results Format Preferred (circle): PAPER DISK E-MAIL  
0 9A01

If more than one search is submitted, please prioritize searches in order of need.

\*\*\*\*\*  
Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Antiangiogenic peptides  
Inventors (please provide full names): Henkin, Jack; Hanin, Fortuna;  
Bradley, Michael F.; Calver, Douglas M.; Schneiders, Andrew J.  
Earliest Priority Filing Date: 5/22/98

\*For Sequence Searches Only\* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Please find any of the amino acids enclosed.

Specie 13 of claim 12 was elected.

Thanks.

Ex # 1, 3, 4, 5, 8, 11, 12, 18, 28, 42, 43,  
46, 47, 49, & 50-66 anti-angiogenic  
activity shown (inhibited h-endothelial cell migration)

Treating cancer, arthritis, psoriasis, angiogenesis  
of the eye associated with infection or surgical,  
macular degeneration, diabetic retinopathy  
Use as anti-angiogenesis (cancer)

### STAFF USE ONLY

	Type of Search	Vendors and cost where applicable
Searcher: <u>John</u>	NA Sequence (#) _____	STN <u>✓</u>
Searcher Phone #: <u>4458</u>	AA Sequence (#) <u>5</u>	Dialog _____
Searcher Location: _____	Structure (#) _____	Questel/Orbit _____
Date Searcher Picked Up: <u>3/5</u>	Bibliographic _____	Dr.Link _____
Date Completed: <u>3/5</u>	Litigation _____	Lexis/Nexis _____
Searcher Prep & Review Time: _____	Fulltext _____	Sequence Systems _____
Clerical Prep Time: <u>30</u>	Patent Family _____	WWW/Internet _____
Online Time: <u>+ 45</u>	Other _____	Other (specify) _____

Claims 1-13 are attached

=> fil reg

FILE 'REGISTRY' ENTERED AT 08:46:35 ON 05 MAR 2001  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 4 MAR 2001 HIGHEST RN 325683-70-3  
DICTIONARY FILE UPDATES: 4 MAR 2001 HIGHEST RN 325683-70-3

TSCA INFORMATION NOW CURRENT THROUGH July 8, 2000

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT  
for details.

=> d l32 tot sqide can

L32 ANSWER 1 OF 8 REGISTRY COPYRIGHT 2001 ACS  
RN 251585-91-8 REGISTRY  
CN L-Prolinamide, N-acetyl-N-methylglycylglycyl-L-valyl-L-alloisoleucyl-L-  
threonyl-L-norvalyl-L-isoleucyl-L-arginyl-N-ethyl-, mono(trifluoroacetate)  
(salt) (9CI) (CA INDEX NAME)  
FS PROTEIN SEQUENCE; STEREOSEARCH  
SQL 9  
NTE modified


type	location	description
terminal mod.	Gly-1	N-acetyl
uncommon	Nva-6	-
modification	-	undetermined modification
modification	Gly-1	methyl<Me>

SEQ 1 GGVITXIRP  
MF C46 H83 N13 O11 . C2 H F3 O2  
SR CA  
LC STN Files: CA, CAPLUS  
  
CM 1  
  
CRN 251585-90-7  
CMF C46 H83 N13 O11

Absolute stereochemistry.

Point of Contact:  
Jan Delany  
Librarian-Physical Sciences  
CM1 1E01 Tel: 308-4498

PAGE 1-A




PAGE 1-B

NH<sub>2</sub>Et

CM 2

CRN 76-05-1

CMF C2 H F3 O2



1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:23191


L32 ANSWER 2 OF 8 REGISTRY COPYRIGHT 2001 ACS  
 RN 251585-90-7 REGISTRY  
 CN **L-Prolinamide, N-acetyl-N-methylglycylglycyl-L-valyl-L-alloisoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-L-arginyl-N-ethyl- (9CI) (CA INDEX NAME)**  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 SQL 9  
 NTE modified

type	----- location -----	description
terminal mod.	Gly-1 -	N-acetyl
uncommon	Nva-6 -	-
modification	Gly-1 -	methyl<Me>

SEQ 1 GGVITXIRP  
 MF **C46 H83 N13 O11**  
 CI COM  
 SR CA

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

NHet

L32 ANSWER 3 OF 8 REGISTRY COPYRIGHT 2001 ACS

RN 251584-19-7 REGISTRY

CN L-Prolinamide, N-acetyl-N-methylglycylglycyl-L-valyl-D-alloisoleucyl-L-threonyl-D-norvalyl-L-isoleucyl-L-arginyl-N-ethyl- (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH

SQL 9

NTE modified

type	location		description
terminal mod.	Gly-1	-	N-acetyl
uncommon	Nva-6	-	-
modification	Gly-1	-	methyl<Me>

SEQ 1 GGVITXIRP


MF C46 H83 N13 O11

SR CA

LC STN Files: CA, CAPLUS

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

NH<sub>2</sub>

1 REFERENCES IN FILE CA (1967 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:23191

L32 ANSWER 4 OF 8 REGISTRY COPYRIGHT 2001 ACS

RN 251584-12-0 REGISTRY

CN **L-Prolinamide, N-acetyl-N-methylglycylglycyl-L-valyl-D-alloisoleucyl-L-threonyl-L-valyl-L-isoleucyl-L-arginyl-N-ethyl- (9CI)** (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH

SQL 9


NTE modified

type	location	description
terminal mod.	Gly-1	N-acetyl
modification	Gly-1	methyl<Me>

SEQ 1 GGVITVIRP  
 MF C46 H83 N13 O11  
 SR CA  
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

NH<sub>2</sub>

1 REFERENCES IN FILE CA (1967 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:23191

L32 ANSWER 5 OF 8 REGISTRY COPYRIGHT 2001 ACS

RN 251579-96-1 REGISTRY

CN L-Prolinamide, N-acetyl-N-methylglycylglycyl-L-valyl-3-(2-thienyl)-D-alanyl-L-threonyl-L-norvalyl-L-isoleucyl-L-arginyl-N-ethyl-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH  
 SQL 9  
 NTE modified

type	location		description
terminal mod.	Gly-1	-	N-acetyl
uncommon	Thi-4	-	-
uncommon	Nva-6	-	-
modification	-	-	undetermined modification
modification	Gly-1	-	methyl<Me>

SEQ 1 GGVXTXIRP  
 MF C47 H79 N13 O11 S . C2 H F3 O2  
 SR CA  
 LC STN Files: CA, CAPLUS


CM 1

CRN 251579-95-0


CMF C47 H79 N13 O11 S

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



CM 2

CRN 76-05-1

CMF C2 H F3 O2



1 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:23191

L32 ANSWER 6 OF 8 REGISTRY COPYRIGHT 2001 ACS

RN **251579-95-0** REGISTRY

CN L-Prolinamide, N-acetyl-N-methylglycylglycyl-L-valyl-3-(2-thienyl)-D-alanyl-L-threonyl-L-norvalyl-L-isoleucyl-L-arginyl-N-ethyl- (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH

SQL 9

NTE modified

type	-----	location	-----	description
terminal mod.	Gly-1	-		N-acetyl
uncommon	Thi-4	-		-
uncommon	Nva-6	-		-
modification	Gly-1	-		methyl<Me>

SEQ 1 GGVXTXIRP

MF **C47 H79 N13 O11 S**


CI COM

SR CA


LC STN Files: CA, CAPLUS

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1967 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:23191

L32 ANSWER 7 OF 8 REGISTRY COPYRIGHT 2001 ACS  
 RN 251579-56-3 REGISTRY  
 CN L-Prolinamide, N-acetyl-N-methylglycylglycyl-L-valyl-D-alloisoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-L-arginyl-N-ethyl-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 SQL 9  
 NTE modified

type	----- location -----	description
terminal mod.	Gly-1 -	N-acetyl
uncommon	Nva-6 -	-
modification	- -	undetermined modification
modification	Gly-1 -	methyl<Me>


SEQ 1 GGVITXIRP  
 MF C46 H83 N13 O11 . C2 H F3 O2  
 SR CA  
 LC STN Files: CA, CAPLUS

CM 1

CRN 251579-55-2  
 CMF C46 H83 N13 O11

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

NH<sub>2</sub>Et

CM 2

CRN 76-05-1

CMF C2 H F3 O2



1 REFERENCES IN FILE CA (1967 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:23191

L32 ANSWER 8 OF 8 REGISTRY COPYRIGHT 2001 ACS

RN 251579-55-2 REGISTRY

CN L-Prolinamide, N-acetyl-N-methylglycylglycyl-L-valyl-D-alloisoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-L-arginyl-N-ethyl- (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH

SQL 9

NTE modified

type	-----	location	-----	description
terminal mod.	Gly-1	-		N-acetyl
uncommon	Nva-6	-		-
modification	Gly-1	-		methyl<Me>

SEQ 1 GGVITXIRP

MF C46 H83 N13 O11


CI COM

SR CA

LC STN Files: CA, CAPLUS

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

NHET

1 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:23191

=&gt; d his 133-

(FILE 'REGISTRY' ENTERED AT 08:00:38 ON 05 MAR 2001)  
SAV L32 MOEZIE316/A  
SAV L14 MOEZIE316A/A

L33 FILE 'HCAOLD' ENTERED AT 08:46:09 ON 05 MAR 2001  
0 S L32

L34 FILE 'HCAPLUS' ENTERED AT 08:46:14 ON 05 MAR 2001  
1 S L32

L35 FILE 'USPATFULL' ENTERED AT 08:46:19 ON 05 MAR 2001  
0 S L32

FILE 'REGISTRY' ENTERED AT 08:46:35 ON 05 MAR 2001

=&gt; fil hcaplus

FILE 'HCAPLUS' ENTERED AT 08:47:12 ON 05 MAR 2001  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1967 - 5 Mar 2001 VOL 134 ISS 11  
FILE LAST UPDATED: 4 Mar 2001 (20010304/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGlstrY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

Now you can extend your author, patent assignee, patent information, and title searches back to 1907. The records from 1907-1966 now have this searchable data in CAOLD. You now have electronic access to all of CA: 1907 to 1966 in CAOLD and 1967 to the present in HCAPLUS on STN.

=> d 134 all

L34 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2001 ACS

AN 1999:764071 HCAPLUS

DN 132:23191

TI Preparation of peptide antiangiogenic drugs

IN Henkin, Jack; Haviv, Fortuna; Bradley, Michael F.; Calvin, Douglas M.; Schneider, Andrew J.

PA Abbott Laboratories, USA

SO PCT Int. Appl., 223 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C07K014-78

ICS A61K038-39; G01N033-68

CC 34-3 (Amino Acids, Peptides, and Proteins)

Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9961476	A1	19991202	WO 1999-US11448	19990521
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9944075	A1	19991213	AU 1999-44075	19990521
	EP 1078002	A1	20010228	EP 1999-927091	19990521
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI, RO			
	NO 2000005890	A	20010112	NO 2000-5890	20001121
PRAI	US 1998-83745		19980522		
	US 1999-250574		19990216		
	US 1999-277466		19990326		
	WO 1999-US11448		19990521		
OS	MARPAT 132:23191				
AB	Peptides A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10 (A0 is H or an acyl group; A10 is OH or an amino acid amide; A1-9 are amino acyl residues) or their pharmaceutically acceptable salts, esters, solvates, or prodrugs were prepd. for the treatment of angiogenesis. Thus, N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-Pro-NHET was prepd. by the solid-phase method and assayed for in vitro angiogenic activity (87.3% at 20 nM and 76.9 at 10 nM).				
ST	peptide prepn antiangiogenic activity				
IT	Eye, disease (diabetic retinopathy; prepn. of peptide antiangiogenic drugs)				
IT	Eye, disease (macula, degeneration; prepn. of peptide antiangiogenic drugs)				
IT	Angiogenesis inhibitors				
	Antiarthritics				
	Antitumor agents				
	Psoriasis				
	(prepn. of peptide antiangiogenic drugs)				

IT Peptides, preparation  
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of peptide antiangiogenic drugs)

IT 251579-31-4P 251579-32-5P 251579-33-6P 251579-34-7P 251579-35-8P  
 251579-36-9P 251579-37-0P 251579-38-1P 251579-39-2P 251579-40-5P  
 251579-41-6P 251579-42-7P 251579-43-8P 251579-44-9P 251579-45-0P  
 251579-46-1P 251579-47-2P 251579-48-3P 251579-49-4P 251579-50-7P  
 251579-51-8P 251579-52-9P 251579-53-0P 251579-54-1P  
**251579-55-2P 251579-56-3P** 251579-57-4P 251579-58-5P  
 251579-59-6P 251579-60-9P 251579-61-0P 251579-62-1P 251579-63-2P  
 251579-64-3P 251579-65-4P 251579-66-5P 251579-67-6P 251579-68-7P  
 251579-69-8P 251579-70-1P 251579-71-2P 251579-72-3P 251579-73-4P  
 251579-74-5P 251579-75-6P 251579-76-7P 251579-77-8P 251579-78-9P  
 251579-79-0P 251579-80-3P 251579-81-4P 251579-82-5P 251579-83-6P  
 251579-84-7P 251579-85-8P 251579-86-9P 251579-87-0P 251579-88-1P  
 251579-89-2P 251579-90-5P 251579-91-6P 251579-92-7P 251579-93-8P  
 251579-94-9P **251579-95-0P 251579-96-1P** 251579-97-2P  
 251579-98-3P 251579-99-4P 251580-00-4P 251580-01-5P 251580-02-6P  
 251580-03-7P 251580-04-8P 251580-05-9P 251580-06-0P 251580-07-1P  
 251580-08-2P 251580-09-3P 251580-10-6P 251580-11-7P 251580-12-8P  
 251580-13-9P 251580-14-0P 251580-15-1P 251580-16-2P 251580-17-3P  
 251580-18-4P 251580-19-5P 251580-20-8P 251580-21-9P 251580-22-0P  
 251580-23-1P 251580-24-2P 251580-25-3P 251580-26-4P 251580-27-5P  
 251580-28-6P 251580-29-7P 251580-30-0P 251580-31-1P 251580-32-2P  
 251580-33-3P 251580-34-4P 251580-35-5P 251580-36-6P 251580-37-7P  
 251580-38-8P 251580-39-9P 251580-40-2P 251580-41-3P 251580-42-4P  
 251580-43-5P 251580-44-6P 251580-45-7P 251580-46-8P 251580-47-9P  
 251580-48-0P 251580-49-1P 251580-50-4P 251580-51-5P 251580-52-6P  
 251580-54-8P 251580-55-9P 251580-57-1P 251580-58-2P 251580-60-6P  
 251580-61-7P 251580-63-9P 251580-64-0P 251580-66-2P 251580-67-3P  
 251580-69-5P 251580-70-8P 251580-72-0P 251580-73-1P 251580-75-3P  
 251580-76-4P 251580-78-6P 251580-79-7P 251580-81-1P 251580-82-2P  
 251580-84-4P 251580-85-5P 251580-87-7P 251580-88-8P 251580-90-2P  
 251580-91-3P 251580-93-5P 251580-94-6P 251580-96-8P 251580-97-9P  
 251580-99-1P 251581-00-7P 251581-02-9P 251581-03-0P 251581-05-2P  
 251581-07-4P 251581-08-5P 251581-10-9P 251581-11-0P 251581-13-2P  
 251581-14-3P 251581-15-4P 251581-16-5P 251581-17-6P 251581-18-7P  
 251581-19-8P 251581-20-1P 251581-21-2P 251581-22-3P 251581-23-4P  
 251581-24-5P 251581-25-6P 251581-26-7P 251581-27-8P 251581-28-9P  
 251581-29-0P 251581-30-3P 251581-31-4P 251581-32-5P 251581-33-6P  
 251581-34-7P 251581-35-8P 251581-36-9P 251581-37-0P 251581-38-1P  
 251581-39-2P 251581-40-5P 251581-41-6P 251581-42-7P 251581-43-8P  
 251581-44-9P 251581-45-0P 251581-46-1P 251581-47-2P 251581-48-3P  
 251581-49-4P 251581-50-7P 251581-51-8P 251581-52-9P 251581-53-0P  
 251581-54-1P 251581-55-2P 251581-56-3P 251581-57-4P 251581-58-5P  
 251581-59-6P 251581-60-9P 251581-61-0P 251581-62-1P 251581-63-2P  
 251581-64-3P 251581-65-4P 251581-66-5P 251581-67-6P 251581-68-7P  
 251581-69-8P 251581-70-1P 251581-71-2P 251581-72-3P 251581-73-4P  
 251581-74-5P 251581-75-6P 251581-76-7P 251581-77-8P 251581-78-9P  
 251581-79-0P 251581-80-3P 251581-81-4P 251581-82-5P 251581-83-6P  
 251581-84-7P 251581-85-8P 251581-86-9P  
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of peptide antiangiogenic drugs)

IT 251581-87-0P 251581-88-1P 251581-89-2P 251581-90-5P 251581-91-6P  
 251581-92-7P 251581-93-8P 251581-94-9P 251581-95-0P 251581-96-1P  
 251581-97-2P 251581-98-3P 251581-99-4P 251582-00-0P 251582-01-1P  
 251582-02-2P 251582-03-3P 251582-04-4P 251582-05-5P 251582-06-6P  
 251582-07-7P 251582-08-8P 251582-09-9P 251582-10-2P 251582-11-3P  
 251582-12-4P 251582-13-5P 251582-14-6P 251582-15-7P 251582-16-8P  
 251582-17-9P 251582-18-0P 251582-19-1P 251582-20-4P 251582-21-5P  
 251582-22-6P 251582-23-7P 251582-24-8P 251582-25-9P 251582-26-0P  
 251582-27-1P 251582-28-2P 251582-29-3P 251582-30-6P 251582-31-7P

251582-32-8P	251582-33-9P	251582-34-0P	251582-35-1P	251582-36-2P
251582-37-3P	251582-38-4P	251582-39-5P	251582-40-8P	251582-41-9P
251582-42-0P	251582-43-1P	251582-44-2P	251582-45-3P	251582-46-4P
251582-47-5P	251582-48-6P	251582-49-7P	251582-50-0P	251582-51-1P
251582-52-2P	251582-53-3P	251582-54-4P	251582-55-5P	251582-56-6P
251582-57-7P	251582-58-8P	251582-59-9P	251582-60-2P	251582-61-3P
251582-62-4P	251582-63-5P	251582-64-6P	251582-65-7P	251582-66-8P
251582-67-9P	251582-68-0P	251582-69-1P	251582-70-4P	251582-71-5P
251582-72-6P	251582-73-7P	251582-74-8P	251582-75-9P	251582-76-0P
251582-77-1P	251582-78-2P	251582-79-3P	251582-80-6P	251582-81-7P
251582-82-8P	251582-83-9P	251582-84-0P	251582-85-1P	251582-86-2P
251582-87-3P	251582-88-4P	251582-89-5P	251582-90-8P	251582-91-9P
251582-92-0P	251582-93-1P	251582-94-2P	251582-95-3P	251582-96-4P
251582-97-5P	251582-98-6P	251582-99-7P	251583-00-3P	251583-01-4P
251583-02-5P	251583-03-6P	251583-04-7P	251583-05-8P	251583-06-9P
251583-07-0P	251583-08-1P	251583-09-2P	251583-10-5P	251583-11-6P
251583-12-7P	251583-13-8P	251583-14-9P	251583-15-0P	251583-16-1P
251583-17-2P	251583-18-3P	251583-19-4P	251583-20-7P	251583-21-8P
251583-22-9P	251583-23-0P	251583-24-1P	251583-25-2P	251583-26-3P
251583-27-4P	251583-28-5P	251583-29-6P	251583-30-9P	251583-31-0P
251583-32-1P	251583-33-2P	251583-34-3P	251583-35-4P	251583-36-5P
251583-37-6P	251583-38-7P	251583-39-8P	251583-40-1P	251583-41-2P
251583-42-3P	251583-43-4P	251583-44-5P	251583-45-6P	251583-46-7P
251583-47-8P	251583-48-9P	251583-49-0P	251583-50-3P	251583-51-4P
251583-52-5P	251583-53-6P	251583-54-7P	251583-55-8P	251583-56-9P
251583-57-0P	251583-58-1P	251583-59-2P	251583-60-5P	251583-61-6P
251583-62-7P	251583-63-8P	251583-64-9P	251583-65-0P	251583-66-1P
251583-67-2P	251583-68-3P	251583-69-4P	251583-70-7P	251583-71-8P
251583-72-9P	251583-73-0P	251583-74-1P	251583-75-2P	251583-76-3P
251583-77-4P	251583-78-5P	251583-79-6P	251583-80-9P	251583-81-0P
251583-82-1P	251583-83-2P	251583-84-3P	251583-85-4P	251583-86-5P
251583-87-6P	251583-88-7P	251583-89-8P	251583-90-1P	251583-91-2P
251583-92-3P	251583-93-4P	251583-96-7P	251583-97-8P	251583-98-9P
251583-99-0P	251584-00-6P	251584-01-7P	251584-02-8P	251584-03-9P
251584-04-0P	251584-05-1P	251584-06-2P	251584-07-3P	251584-08-4P
251584-09-5P	251584-10-8P	251584-11-9P	<b>251584-12-0P</b>	
251584-13-1P	251584-14-2P	251584-15-3P	251584-16-4P	251584-17-5P
251584-18-6P	<b>251584-19-7P</b>	251584-20-0P	251584-21-1P	
251584-22-2P	251584-23-3P			

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of peptide antiangiogenic drugs)

IT	251584-24-4P	251584-25-5P	251584-26-6P	251584-27-7P	251584-28-8P
	251584-29-9P	251584-30-2P	251584-31-3P	251584-32-4P	251584-33-5P
	251584-34-6P	251584-35-7P	251584-36-8P	251584-37-9P	251584-38-0P
	251584-39-1P	251584-40-4P	251584-41-5P	251584-42-6P	251584-43-7P
	251584-44-8P	251584-45-9P	251584-46-0P	251584-47-1P	251584-48-2P
	251584-49-3P	251584-50-6P	251584-51-7P	251584-52-8P	251584-53-9P
	251584-54-0P	251584-55-1P	251584-56-2P	251584-57-3P	251584-58-4P
	251584-59-5P	251584-60-8P	251584-61-9P	251584-62-0P	251584-63-1P
	251584-64-2P	251584-65-3P	251584-66-4P	251584-67-5P	251584-68-6P
	251584-69-7P	251584-70-0P	251584-71-1P	251584-72-2P	251584-73-3P
	251584-74-4P	251584-75-5P	251584-76-6P	251584-77-7P	251584-78-8P
	251584-79-9P	251584-80-2P	251584-81-3P	251584-82-4P	251584-83-5P
	251584-84-6P	251584-85-7P	251584-86-8P	251584-87-9P	251584-88-0P
	251584-89-1P	251584-90-4P	251584-91-5P	251584-92-6P	251584-93-7P
	251584-94-8P	251584-95-9P	251584-96-0P	251584-97-1P	251584-98-2P
	251584-99-3P	251585-00-9P	251585-01-0P	251585-02-1P	251585-03-2P
	251585-04-3P	251585-05-4P	251585-06-5P	251585-07-6P	251585-08-7P
	251585-09-8P	251585-10-1P	251585-11-2P	251585-12-3P	251585-13-4P
	251585-14-5P	251585-15-6P	251585-16-7P	251585-17-8P	251585-18-9P
	251585-19-0P	251585-20-3P	251585-21-4P	251585-22-5P	251585-23-6P
	251585-24-7P	251585-25-8P	251585-26-9P	251585-27-0P	251585-28-1P
	251585-29-2P	251585-30-5P	251585-31-6P	251585-32-7P	251585-33-8P
	251585-34-9P	251585-35-0P	251585-36-1P	251585-37-2P	251585-38-3P

251585-39-4P	251585-40-7P	251585-41-8P	251585-42-9P	251585-43-0P
251585-44-1P	251585-45-2P	251585-46-3P	251585-47-4P	251585-48-5P
251585-49-6P	251585-50-9P	251585-51-0P	251585-52-1P	251585-53-2P
251585-54-3P	251585-55-4P	251585-56-5P	251585-57-6P	251585-58-7P
251585-59-8P	251585-60-1P	251585-61-2P	251585-62-3P	251585-63-4P
251585-64-5P	251585-65-6P	251585-66-7P	251585-67-8P	251585-68-9P
251585-69-0P	251585-70-3P	251585-71-4P	251585-72-5P	251585-73-6P
251585-74-7P	251585-75-8P	251585-76-9P	251585-77-0P	251585-78-1P
251585-79-2P	251585-80-5P	251585-81-6P	251585-82-7P	251585-83-8P
251585-84-9P	251585-85-0P	251585-86-1P	251585-87-2P	251585-89-4P
<b>251585-91-8P</b>	251585-93-0P	251585-95-2P	251585-97-4P	
251585-99-6P	251586-01-3P	251586-03-5P	251586-05-7P	251586-07-9P
251586-09-1P	251586-11-5P	251586-13-7P	251586-15-9P	251586-16-0P
251586-17-1P	251586-18-2P	251586-19-3P	251586-20-6P	251586-21-7P
251586-22-8P	251586-23-9P	251586-24-0P	251586-25-1P	251586-26-2P
251586-27-3P	251586-28-4P	251586-29-5P	251586-30-8P	251586-32-0P
251586-33-1P	251586-34-2P	251586-35-3P	251586-36-4P	251900-41-1P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of peptide antiangiogenic drugs)

IT 59-67-6, Nicotinic acid, reactions 79-09-4, Propionic acid, reactions 88-14-2, 2-Furoic acid 107-92-6, Butanoic acid, reactions 109-85-3, 2-Methoxyethylamine 138-59-0, Shikimic acid 142-62-1, Hexanoic acid, reactions 625-45-6, Methoxyacetic acid 2516-47-4, Cyclopropanemethanamine 3222-56-8, 2-Methylnicotinic acid 4442-85-7, 2-Cyclohexylethylamine 5292-21-7, Cyclohexylacetic acid 5913-13-3, 1-Cyclohexylethylamine 7154-73-6, 1-(2-Aminoethyl)pyrrolidine 16874-33-2, Tetrahydro-2-furoic acid 27578-60-5, 1-(2-Aminoethyl)piperidine 101711-55-1

RL: RCT (Reactant)

(prepn. of peptide antiangiogenic drugs)

RE.CNT 4

RE

- (1) Abbott Lab; WO 9741824 A 1997 HCAPLUS
- (2) Grace W R & Co; EP 0443404 A 1991 HCAPLUS
- (3) Univ Northwestern; WO 9316716 A 1993 HCAPLUS
- (4) Univ Northwestern; WO 9841542 A 1998 HCAPLUS

=> d his 136-

FILE 'REGISTRY' ENTERED AT 08:48:10 ON 05 MAR 2001

E 'SAR-GLY-VAL-ILE-THR-NVA-ILE-ARG-PRO'/SQEP

L36 2 S E3  
 L37 2 S L36 NOT L32  
 L38 282 S G[VN][IA]T.IRP/SQSP  
 L39 281 S L38 AND SQL<=20  
 SAV L39 MOEZIE316B/A

FILE 'HCAPLUS' ENTERED AT 08:51:31 ON 05 MAR 2001

L40 1 S L39  
 L41 1 S L37  
 L42 1 S L40,L41,L34

=> d all

L42 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2001 ACS

AN 1999:764071 HCAPLUS

DN 132:23191

TI Preparation of peptide antiangiogenic drugs

IN Henkin, Jack; Haviv, Fortuna; Bradley, Michael F.; Calvin, Douglas M.;

Schneider, Andrew J.  
 PA Abbott Laboratories, USA  
 SO PCT Int. Appl., 223 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM C07K014-78  
 ICS A61K038-39; G01N033-68  
 CC 34-3 (Amino Acids, Peptides, and Proteins)  
 Section cross-reference(s): 1  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9961476	A1	19991202	WO 1999-US11448	19990521
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9944075	A1	19991213	AU 1999-44075	19990521
	EP 1078002	A1	20010228	EP 1999-927091	19990521
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI, RO			
	NO 2000005890	A	20010112	NO 2000-5890	20001121
PRAI	US 1998-83745		19980522		
	US 1999-250574		19990216		
	US 1999-277466		19990326		
	WO 1999-US11448		19990521		
OS	MARPAT 132:23191				
AB	Peptides A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10 (A0 is H or an acyl group; A10 is OH or an amino acid amide; A1-9 are amino acyl residues) or their pharmaceutically acceptable salts, esters, solvates, or prodrugs were prepd. for the treatment of angiogenesis. Thus, N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-Pro-NHEt was prepd. by the solid-phase method and assayed for in vitro angiogenic activity (87.3% at 20 nM and 76.9 at 10 nM).				
ST	peptide prepn antiangiogenic activity				
IT	Eye, disease (diabetic retinopathy; prepn. of peptide antiangiogenic drugs)				
IT	Eye, disease (macula, degeneration; prepn. of peptide antiangiogenic drugs)				
IT	Angiogenesis inhibitors Antiarthritics Antitumor agents Psoriasis (prepn. of peptide antiangiogenic drugs)				
IT	Peptides, preparation RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of peptide antiangiogenic drugs)				
IT	251579-31-4P	251579-32-5P	251579-33-6P		
	251579-34-7P	251579-35-8P	251579-36-9P		
	251579-37-0P	251579-38-1P	251579-39-2P		
	251579-40-5P	251579-41-6P	251579-42-7P		
	251579-43-8P	251579-44-9P	251579-45-0P		
	251579-46-1P	251579-47-2P	251579-48-3P		
	251579-49-4P	251579-50-7P	251579-51-8P		
	251579-52-9P	251579-53-0P	251579-54-1P		
	251579-55-2P	251579-56-3P	251579-57-4P	251579-58-5P	
	251579-59-6P	251579-60-9P	251579-61-0P	251579-62-1P	
	251579-63-2P	251579-64-3P	251579-65-4P	251579-66-5P	
	251579-67-6P	251579-68-7P	251579-69-8P	251579-70-1P	251579-71-2P
	251579-72-3P	251579-73-4P	251579-74-5P	251579-75-6P	251579-76-7P

251579-77-8P 251579-78-9P 251579-79-0P 251579-80-3P  
 251579-81-4P 251579-82-5P 251579-83-6P 251579-84-7P 251579-85-8P  
 251579-86-9P 251579-87-0P 251579-88-1P 251579-89-2P 251579-90-5P  
 251579-91-6P 251579-92-7P 251579-93-8P 251579-94-9P  
 251579-95-0P 251579-96-1P 251579-97-2P 251579-98-3P  
 251579-99-4P 251580-00-4P 251580-01-5P  
 251580-02-6P 251580-03-7P 251580-04-8P  
 251580-05-9P 251580-06-0P 251580-07-1P  
 251580-08-2P 251580-09-3P 251580-10-6P  
 251580-11-7P 251580-12-8P 251580-13-9P  
 251580-14-0P 251580-15-1P 251580-16-2P  
 251580-17-3P 251580-18-4P 251580-19-5P  
 251580-20-8P 251580-21-9P 251580-22-0P  
 251580-23-1P 251580-24-2P 251580-25-3P  
 251580-26-4P 251580-27-5P 251580-28-6P  
 251580-29-7P 251580-30-0P 251580-31-1P  
 251580-32-2P 251580-33-3P 251580-34-4P  
 251580-35-5P 251580-36-6P 251580-37-7P  
 251580-38-8P 251580-39-9P 251580-40-2P  
 251580-41-3P 251580-42-4P 251580-43-5P  
 251580-44-6P 251580-45-7P 251580-46-8P  
 251580-47-9P 251580-48-0P 251580-49-1P  
 251580-50-4P 251580-51-5P 251580-52-6P  
 251580-54-8P 251580-55-9P 251580-57-1P  
 251580-58-2P 251580-60-6P 251580-61-7P  
 251580-63-9P 251580-64-0P 251580-66-2P  
 251580-67-3P 251580-69-5P 251580-70-8P  
 251580-72-0P 251580-73-1P 251580-75-3P  
 251580-76-4P 251580-78-6P 251580-79-7P 251580-81-1P  
 251580-82-2P 251580-84-4P 251580-85-5P 251580-87-7P 251580-88-8P  
 251580-90-2P 251580-91-3P 251580-93-5P 251580-94-6P 251580-96-8P  
 251580-97-9P 251580-99-1P 251581-00-7P 251581-02-9P 251581-03-0P  
 251581-05-2P 251581-07-4P 251581-08-5P 251581-10-9P 251581-11-0P  
 251581-13-2P 251581-14-3P 251581-15-4P 251581-16-5P  
 251581-17-6P 251581-18-7P 251581-19-8P 251581-20-1P  
 251581-21-2P 251581-22-3P 251581-23-4P 251581-24-5P  
 251581-25-6P 251581-26-7P 251581-27-8P 251581-28-9P 251581-29-0P  
 251581-30-3P 251581-31-4P 251581-32-5P 251581-33-6P 251581-34-7P  
 251581-35-8P 251581-36-9P 251581-37-0P 251581-38-1P 251581-39-2P  
 251581-40-5P 251581-41-6P 251581-42-7P 251581-43-8P 251581-44-9P  
 251581-45-0P 251581-46-1P 251581-47-2P 251581-48-3P 251581-49-4P  
 251581-50-7P 251581-51-8P 251581-52-9P 251581-53-0P 251581-54-1P  
 251581-55-2P 251581-56-3P 251581-57-4P 251581-58-5P 251581-59-6P  
 251581-60-9P 251581-61-0P 251581-62-1P 251581-63-2P 251581-64-3P  
 251581-65-4P 251581-66-5P 251581-67-6P 251581-68-7P 251581-69-8P  
 251581-70-1P 251581-71-2P 251581-72-3P 251581-73-4P 251581-74-5P  
 251581-75-6P 251581-76-7P 251581-77-8P 251581-78-9P 251581-79-0P  
 251581-80-3P 251581-81-4P 251581-82-5P 251581-83-6P 251581-84-7P  
 251581-85-8P 251581-86-9P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of peptide antiangiogenic drugs)

IT 251581-87-0P 251581-88-1P 251581-89-2P 251581-90-5P 251581-91-6P  
 251581-92-7P 251581-93-8P 251581-94-9P 251581-95-0P 251581-96-1P  
 251581-97-2P 251581-98-3P 251581-99-4P  
 251582-00-0P 251582-01-1P 251582-02-2P  
 251582-03-3P 251582-04-4P 251582-05-5P  
 251582-06-6P 251582-07-7P 251582-08-8P  
 251582-09-9P 251582-10-2P 251582-11-3P  
 251582-12-4P 251582-13-5P 251582-14-6P  
 251582-15-7P 251582-16-8P 251582-17-9P 251582-18-0P  
 251582-19-1P 251582-20-4P 251582-21-5P  
 251582-22-6P 251582-23-7P 251582-24-8P  
 251582-25-9P 251582-26-0P 251582-27-1P 251582-28-2P  
 251582-29-3P 251582-30-6P 251582-31-7P 251582-32-8P 251582-33-9P

251582-34-0P 251582-35-1P 251582-36-2P 251582-37-3P 251582-38-4P  
 251582-39-5P 251582-40-8P 251582-41-9P 251582-42-0P 251582-43-1P  
 251582-44-2P 251582-45-3P 251582-46-4P 251582-47-5P 251582-48-6P  
 251582-49-7P 251582-50-0P 251582-51-1P 251582-52-2P  
 251582-53-3P 251582-54-4P 251582-55-5P  
 251582-56-6P 251582-57-7P 251582-58-8P  
 251582-59-9P 251582-60-2P 251582-61-3P 251582-62-4P  
 251582-63-5P 251582-64-6P 251582-65-7P 251582-66-8P  
 251582-67-9P 251582-68-0P 251582-69-1P 251582-70-4P  
 251582-71-5P 251582-72-6P 251582-73-7P  
 251582-74-8P 251582-75-9P 251582-76-0P 251582-77-1P 251582-78-2P  
 251582-79-3P 251582-80-6P 251582-81-7P 251582-82-8P 251582-83-9P  
 251582-84-0P 251582-85-1P 251582-86-2P 251582-87-3P  
 251582-88-4P 251582-89-5P 251582-90-8P 251582-91-9P 251582-92-0P  
 251582-93-1P 251582-94-2P 251582-95-3P 251582-96-4P 251582-97-5P  
 251582-98-6P 251582-99-7P 251583-00-3P 251583-01-4P 251583-02-5P  
 251583-03-6P 251583-04-7P 251583-05-8P  
 251583-06-9P 251583-07-0P 251583-08-1P  
 251583-09-2P 251583-10-5P 251583-11-6P  
 251583-12-7P 251583-13-8P 251583-14-9P  
 251583-15-0P 251583-16-1P 251583-17-2P  
 251583-18-3P 251583-19-4P 251583-20-7P  
 251583-21-8P 251583-22-9P 251583-23-0P  
 251583-24-1P 251583-25-2P 251583-26-3P  
 251583-27-4P 251583-28-5P 251583-29-6P  
 251583-30-9P 251583-31-0P 251583-32-1P  
 251583-33-2P 251583-34-3P 251583-35-4P  
 251583-36-5P 251583-37-6P 251583-38-7P  
 251583-39-8P 251583-40-1P 251583-41-2P  
 251583-42-3P 251583-43-4P 251583-44-5P  
 251583-45-6P 251583-46-7P 251583-47-8P  
 251583-48-9P 251583-49-0P 251583-50-3P  
 251583-51-4P 251583-52-5P 251583-53-6P  
 251583-54-7P 251583-55-8P 251583-56-9P  
 251583-57-0P 251583-58-1P 251583-59-2P  
 251583-60-5P 251583-61-6P 251583-62-7P  
 251583-63-8P 251583-64-9P 251583-65-0P  
 251583-66-1P 251583-67-2P 251583-68-3P  
 251583-69-4P 251583-70-7P 251583-71-8P  
 251583-72-9P 251583-73-0P 251583-74-1P  
 251583-75-2P 251583-76-3P 251583-77-4P  
 251583-78-5P 251583-79-6P 251583-80-9P  
 251583-81-0P 251583-82-1P 251583-83-2P  
 251583-84-3P 251583-85-4P 251583-86-5P 251583-87-6P  
 251583-88-7P 251583-89-8P 251583-90-1P  
 251583-91-2P 251583-92-3P 251583-93-4P 251583-96-7P  
 251583-97-8P 251583-98-9P 251583-99-0P 251584-00-6P 251584-01-7P  
 251584-02-8P 251584-03-9P 251584-04-0P 251584-05-1P  
 251584-06-2P 251584-07-3P 251584-08-4P  
 251584-09-5P 251584-10-8P 251584-11-9P 251584-12-0P  
 251584-13-1P 251584-14-2P 251584-15-3P  
 251584-16-4P 251584-17-5P 251584-18-6P 251584-19-7P  
 251584-20-0P 251584-21-1P 251584-22-2P  
 251584-23-3P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of peptide antiangiogenic drugs)

IT 251584-24-4P 251584-25-5P 251584-26-6P 251584-27-7P 251584-28-8P  
 251584-29-9P 251584-30-2P 251584-31-3P 251584-32-4P 251584-33-5P  
 251584-34-6P 251584-35-7P 251584-36-8P 251584-37-9P 251584-38-0P  
 251584-39-1P 251584-40-4P 251584-41-5P 251584-42-6P 251584-43-7P  
 251584-44-8P 251584-45-9P 251584-46-0P 251584-47-1P 251584-48-2P  
 251584-49-3P 251584-50-6P 251584-51-7P 251584-52-8P 251584-53-9P  
 251584-54-0P 251584-55-1P 251584-56-2P 251584-57-3P  
 251584-58-4P 251584-59-5P 251584-60-8P 251584-61-9P

251584-62-0P 251584-63-1P 251584-64-2P 251584-65-3P  
 251584-66-4P 251584-67-5P 251584-68-6P 251584-69-7P 251584-70-0P  
 251584-71-1P 251584-72-2P 251584-73-3P 251584-74-4P 251584-75-5P  
 251584-76-6P 251584-77-7P 251584-78-8P 251584-79-9P 251584-80-2P  
 251584-81-3P 251584-82-4P **251584-83-5P** 251584-84-6P  
 251584-85-7P **251584-86-8P** 251584-87-9P 251584-88-0P  
 251584-89-1P 251584-90-4P 251584-91-5P 251584-92-6P 251584-93-7P  
 251584-94-8P 251584-95-9P 251584-96-0P 251584-97-1P 251584-98-2P  
 251584-99-3P 251585-00-9P 251585-01-0P 251585-02-1P 251585-03-2P  
 251585-04-3P 251585-05-4P 251585-06-5P 251585-07-6P 251585-08-7P  
 251585-09-8P 251585-10-1P 251585-11-2P 251585-12-3P 251585-13-4P  
 251585-14-5P 251585-15-6P 251585-16-7P 251585-17-8P 251585-18-9P  
 251585-19-0P 251585-20-3P 251585-21-4P 251585-22-5P 251585-23-6P  
 251585-24-7P 251585-25-8P 251585-26-9P 251585-27-0P 251585-28-1P  
 251585-29-2P 251585-30-5P 251585-31-6P 251585-32-7P 251585-33-8P  
 251585-34-9P 251585-35-0P **251585-36-1P 251585-37-2P**  
 251585-38-3P **251585-39-4P 251585-40-7P**  
**251585-41-8P** 251585-42-9P 251585-43-0P 251585-44-1P  
 251585-45-2P 251585-46-3P 251585-47-4P 251585-48-5P 251585-49-6P  
 251585-50-9P 251585-51-0P 251585-52-1P 251585-53-2P 251585-54-3P  
 251585-55-4P 251585-56-5P 251585-57-6P 251585-58-7P 251585-59-8P  
 251585-60-1P 251585-61-2P 251585-62-3P 251585-63-4P  
**251585-64-5P 251585-65-6P 251585-66-7P**  
**251585-67-8P 251585-68-9P** 251585-69-0P 251585-70-3P  
 251585-71-4P 251585-72-5P 251585-73-6P 251585-74-7P 251585-75-8P  
 251585-76-9P **251585-77-0P 251585-78-1P** 251585-79-2P  
 251585-80-5P 251585-81-6P **251585-82-7P** 251585-83-8P  
 251585-84-9P 251585-85-0P **251585-86-1P** 251585-87-2P  
**251585-89-4P 251585-91-8P** 251585-93-0P 251585-95-2P  
 251585-97-4P **251585-99-6P** 251586-01-3P 251586-03-5P  
 251586-05-7P 251586-07-9P 251586-09-1P 251586-11-5P 251586-13-7P  
 251586-15-9P 251586-16-0P 251586-17-1P 251586-18-2P  
**251586-19-3P 251586-20-6P** 251586-21-7P 251586-22-8P  
 251586-23-9P 251586-24-0P 251586-25-1P 251586-26-2P 251586-27-3P  
 251586-28-4P 251586-29-5P 251586-30-8P 251586-32-0P  
**251586-33-1P** 251586-34-2P 251586-35-3P **251586-36-4P**  
 251900-41-1P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Préparation); USES (Uses)

(prepn. of peptide antiangiogenic drugs)

IT 59-67-6, Nicotinic acid, reactions 79-09-4, Propionic acid, reactions 88-14-2, 2-Furoic acid 107-92-6, Butanoic acid, reactions 109-85-3, 2-Methoxyethylamine 138-59-0, Shikimic acid 142-62-1, Hexanoic acid, reactions 625-45-6, Methoxyacetic acid 2516-47-4, Cyclopropanemethanamine 3222-56-8, 2-Methylnicotinic acid 4442-85-7, 2-Cyclohexylethylamine 5292-21-7, Cyclohexylacetic acid 5913-13-3, 1-Cyclohexylethylamine 7154-73-6, 1-(2-Aminoethyl)pyrrolidine 16874-33-2, Tetrahydro-2-furoic acid 27578-60-5, 1-(2-Aminoethyl)piperidine 101711-55-1

RL: RCT (Reactant)

(prepn. of peptide antiangiogenic drugs)

RE.CNT 4

RE

- (1) Abbott Lab; WO 9741824 A 1997 HCAPLUS
- (2) Grace W R & Co; EP 0443404 A 1991 HCAPLUS
- (3) Univ Northwestern; WO 9316716 A 1993 HCAPLUS
- (4) Univ Northwestern; WO 9841542 A 1998 HCAPLUS

=> fil reg

FILE 'REGISTRY' ENTERED AT 08:52:53 ON 05 MAR 2001

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 4 MAR 2001 HIGHEST RN 325683-70-3  
DICTIONARY FILE UPDATES: 4 MAR 2001 HIGHEST RN 325683-70-3

TSCA INFORMATION NOW CURRENT THROUGH July 8, 2000

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT  
for details.

=> d sqide can tot 137

L37 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2001 ACS  
RN 251580-48-0 REGISTRY  
CN L-Prolinamide, N-methylglycylglycyl-L-valyl-D-isoleucyl-L-threonyl-L-  
norvalyl-L-isoleucyl-L-arginyl-N-ethyl-, bis(trifluoroacetate) (salt)  
(9CI) (CA INDEX NAME)  
FS PROTEIN SEQUENCE; STEREOSEARCH  
SQL 9  
NTE modified

type	location	description
uncommon	Sar-1	-
uncommon	Nva-6	-
modification	-	undetermined modification

SEQ 1 XGVITXIRP  
=====


HITS AT: 1-9  
MF C44 H81 N13 O10 . 2 C2 H F3 O2  
SR CA  
LC STN Files: CA, CAPLUS

CM 1

CRN 251580-47-9  
CMF C44 H81 N13 O10

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

NH<sub>2</sub>Et

CM 2

CRN 76-05-1

CMF C2 H F3 O2



1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:23191

L37 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2001 ACS

RN 251580-47-9 REGISTRY

CN L-Prolinamide, N-methylglycylglycyl-L-valyl-D-isoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-L-arginyl-N-ethyl- (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH

SQL 9

NTE modified

type	location			description
uncommon	Sar-1	-	-	
uncommon	Nva-6	-	-	

SEQ 1 XGVITXIRP

=====

HITS AT: 1-9

MF C44 H81 N13 O10


CI COM

SR CA

LC STN Files: CA, CAPLUS

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

NHET

1 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:23191